# A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy

> **NCT01243268** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 674 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Twynsta tablet

## Key facts

- **NCT ID:** NCT01243268
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-21
- **Primary completion:** 2016-06-27
- **Final completion:** 2016-08-18
- **Target enrollment:** 674 (ACTUAL)
- **Last updated:** 2018-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243268, "A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01243268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*